deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 7-arm NCT02648724

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies

Sponsor: Symphogen A/S

Conditions MET Gene Amplification MET Gene Mutation NSCLC Non Small Cell Lung Cancer Oncology
Interventions Sym015
Updated 23 times since 2017 Last updated: May 24, 2022 Started: Mar 31, 2016 Primary completion: Dec 31, 2020 Completion: Dec 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates MET Gene Amplification and MET Gene Mutation and is currently completed. Symphogen A/S leads this study, which shows 23 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Feb 2018 · 4 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Nov 2019 · 5 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jul 2022 · 17 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

23 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

▶ Show 18 earlier versions

  1. Feb 2021 — Jul 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Feb 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Feb 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Feb 2018 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

  12. Oct 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

  13. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  15. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE1_PHASE2

  16. Mar 2017 — May 2017 [monthly]

    Recruiting PHASE1_PHASE2

  17. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE1_PHASE2

  18. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Symphogen A/S
Data source: Symphogen A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Barcelona, Spain , Boston, United States , Chicago, United States , Cleveland, United States , Copenhagen, Denmark , Dallas, United States , Hong Kong, Hong Kong , Houston, United States , Indianapolis, United States and 8 more locations